Clinical Trials Logo

Filter by:
NCT ID: NCT06029907 Not yet recruiting - Pain Clinical Trials

Project HOPES: Healthy Options for Pain and Ending Smoking. A Program for Cancer Survivors.

Start date: July 1, 2024
Phase: Phase 4
Study type: Interventional

The proposed pilot study will develop and test feasibility, acceptability, and signal for efficacy of a smoking cessation and pain management intervention for 20 cancer survivors.

NCT ID: NCT06029894 Recruiting - Alzheimer Disease Clinical Trials

Improving Sleep and AD Biomarkers

Start date: December 15, 2023
Phase: N/A
Study type: Interventional

The purpose of this research is to learn whether a dietary citicoline supplement will impact sleep and cognition. Cognitive disorders include such things as memory disorders and mild cognitive impairment. The investigators are studying persons with mild cognitive impairment (MCI). For this population, the team will assess whether citicoline also impacts biomarkers, a marker of the patient's biological state, in their body. The investigators are interested in learning more about a dietary supplement called citicoline and how it helps sleep, cognition, and markers of Alzheimer's. Previous studies have evaluated this dietary supplement and shown that citicoline may impact cognitive decline. The investigator would like to evaluate if citicoline will also impact sleep and markers of Alzheimer's. This dietary supplement has been assessed in older adults and found to be well tolerated. Citicoline has been used safely in cognitive impairment populations at the same dosage.

NCT ID: NCT06029712 Recruiting - HIV Infections Clinical Trials

Heart Failure Polypill at a Safety Net Hospital

Start date: February 27, 2024
Phase: Phase 2
Study type: Interventional

A novel four-drug regimen for heart failure with reduced ejection fraction (HFrEF) extends patients' life expectancy by an average of 6 years compared to traditional therapies, in addition to improving quality of life. Unfortunately, uptake of this complex multi-drug regimen has been low, especially among underserved communities with barriers to medication adherence. Although combination tablets have transformed access to care for conditions such as HIV and tuberculosis, no combination pill is available for HFrEF. In the proposed study, the investigators will utilize inexpensive over-encapsulation techniques to develop a novel combination pill ("polypill") for patients with HFrEF. In Aim 1, the investigators will conduct stakeholder interviews with patients, providers, and pharmacists to inform the design of a HFrEF polypill. In Aim 2, the investigators will conduct a pilot, single-center, crossover randomized clinical trial to investigate whether, compared to usual care, a HFrEF polypill increases medication adherence among 20-40 adults with HFrEF. Given the high daily pill burden among patients with HIV and HFrEF, the investigators aim to recruit a subgroup of patients with HIV (~10-20 participants) in addition to a subgroup of patients without HIV (~10-20 participants).

NCT ID: NCT06029686 Not yet recruiting - Parkinson Disease Clinical Trials

Vibrotactile Coordinated Reset for Parkinson's Patients of a More Variable Population

Start date: May 2024
Phase: N/A
Study type: Interventional

The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on Parkinson's symptoms of a more variable population. vCR will be administered with a device called the Stanford Glove. vCR is expected to provide patients with a non-invasive alternative to the most widely used treatments such as Levodopa and or deep brain stimulation. Patients will be followed for two years.

NCT ID: NCT06029673 Enrolling by invitation - Clinical trials for Lactation Suppressed

Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss

eLISTA
Start date: February 7, 2024
Phase: Phase 2
Study type: Interventional

Breast pain following second-trimester abortion is common. Breast engorgement and milk leakage following second-trimester perinatal loss and abortion can cause both physical pain and emotional distress. Dopamine agonists have previously been shown to be effective in lactation inhibition for third-trimester fetal/neonatal loss or contraindications to breastfeeding. The investigator's prior work demonstrated that compared to placebo, a single dose of cabergoline was effective in preventing breast symptoms after abortion or loss 18-28 weeks. As lactogenesis starts as early as 16 weeks gestation, the investigators hope to determine the efficacy of cabergoline earlier in the second trimester,16-20 weeks.

NCT ID: NCT06029660 Recruiting - Clinical trials for Aortic Aneurysm, Abdominal

AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion

Start date: April 5, 2024
Phase: N/A
Study type: Interventional

To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR.

NCT ID: NCT06029647 Active, not recruiting - Healthy Clinical Trials

Mangos to Reduce Cardiometabolic Risk Markers

Start date: September 18, 2023
Phase: N/A
Study type: Interventional

This research study will determine the effects of mango consumption on blood pressure, body weight, dietary nutrient/pattern changes, total cholesterol, LDL-cholesterol, VLDL-cholesterol, triglycerides, and HDL-cholesterol in individuals with moderately elevated blood pressure and/or LDL-cholesterol.

NCT ID: NCT06029582 Recruiting - Clinical trials for Pregnancy Termination

VR Headset for Pain During Pregnancy Termination

VRPASAB
Start date: June 20, 2023
Phase: N/A
Study type: Interventional

The goal of this randomized control study is to see if virtual reality headsets (VRHS) are useful in women undergoing surgical pregnancy termination. The main questions it aims to answer are: Do VRHS decrease the pain associated with surgical pregnancy termination Participants will wear the VRHS during the surgery and take a pain survey before and after the procedure. The pain assessment will be compared to placebo headset which will be randomly assigned.

NCT ID: NCT06029517 Recruiting - Clinical trials for Coronary Artery Disease

A Sugar-Sweetened Beverage Reduction Intervention for Native American Men

Start date: July 20, 2022
Phase: N/A
Study type: Interventional

This clinical trial develops and tests a culturally-appropriate educational program (Indigenous SIPin) for reducing sugar-sweetened beverage consumption in men affiliated with Native American athletics communities. Sugary drinks are drinks like pop, soda, and juice. Increased sugar consumption may lead to an increased risk of chronic diseases, including obesity, diabetes, some types of obesity-related cancers, coronary heart disease, hypertension, and dental decay. A culturally sensitive program may help reduce sugar-sweetened beverage consumption in Native American men

NCT ID: NCT06029478 Not yet recruiting - Chondrosarcoma Clinical Trials

Understanding Engagement Trends in Chondrosarcoma Clinical Trials

Start date: October 2024
Phase:
Study type: Observational

Taking part in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. This study will admit a wide range of data on the clinical trial experience of chondrosarcoma patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future chondrosarcoma patients.